alzheimers-congress-2018-posters-abstracts

5 / 28

Page 39
Notes:
conferenceseries.com
Volume 08 Journal of Alzheimers Disease & Parkinsonism Alzheimer's Congress 2018
May 30-31, 2018
May 30-31, 2018 Osaka, Japan
10th World Congress on
Alzheimer's Disease & Dementia
The role of AMP-activated protein kinase as a novel therapeutic target for alzheimer’s disease
Hyunji Jo, Kyu-Yeon, Jun and Youngjoo Kwon
Ewha Womans University, Republic of Korea
Alzheimer ’s Disease (AD) is an aging-associated neurodegenerative disease. AD patients suffer from behavioral deficits,
mental distress and progressive memory impairments. Currently existing AD drugs are merely symptomatic treatments.
Therefore, we need to find a novel therapeutic strategy for AD. Amyloid beta (Aβ), known as a marker of AD, is generated
by cleaving Amyloid-Precursor Protein (APP) with β-secretase (BACE1) and γ-secretase. Identifying effective methods to
suppress the Aβ accumulation has long been of great interest. Recently, AMP-Activated Protein Kinase (AMPK), a serine/
threonine protein kinase, began to be focused as a novel therapeutic target since it has been reported to regulate formation of
Aβ. Thus, in this study, 100 compounds were selected from screening a chemical library containing one million compounds by
in silico study. We finally found YE-06 through chemical modifications and various bioassays. In accordance with the docking
study, YE-06 potentially bound to the AMP binding site of AMPK. Compared to Metformin, which is a well-known AMPK
activator, YE-06 significantly activated AMPK and consequently down-regulated the protein level of BACE1. The mRNA level
of BACE1 was significantly reduced. We showed improvements in the cognition and movement coordination of AD rat model
in YE-06 treated group through water maze test, probe test, passive avoidance test, rotarod test and vertical pole test. YE-06
efficiently increased ACh and decreased the AChE activity. Also, YE-06 significantly reduced neuronal cell death of AD rat
models. Therefore, our results suggest that YE-06 is a potential compound for AD treatment.
Biography
Hyunji Jo has graduated from Konyang University in 2016. She is currently pursuing Doctoral studies in Pharmacy at Ewha Womans University. Her research
focuses on studying the role of AMPK as a novel therapeutic target for Alzheimer’s disease.
Hyunji Jo et al., J Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C4-046